Jeong-Hwan Yoon, Su Myung Jung, Seok Hee Park, Mitsuyasu Kato, Tadashi Yamashita, In-Kyu Lee, Katsuko Sudo, Susumu Nakae, Jin Soo Han, Ok-Hee Kim, Byung-Chul Oh, Takayuki Sumida, Masahiko Kuroda, Ji-Hyeon Ju, Kyeong Cheon Jung, Seong Hoe Park, Dae-Kee Kim and Mizuko Mamura Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes EMBO Molecular Medicine 5
Version of Record online: 11 OCT 2013 | DOI: 10.1002/emmm.201302524
A novel orally bioavailable ALK5 inhibitor is shown to increase antimelanoma CTL-response by inducing Smad4 degradation and Eomes derepression in CD8+ T cells, in addition to systemic inhibition of RSmad phosphorylation by TGF-β type I receptor.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field